Abbott, the parent company of Madison’s Exact Sciences, Thursday announced it has received U.S. Food and Drug Administration authorization for a new biowearable product that helps monitor glucose for diabetes patients.
The product, the Libre Duo 10 Day system, is a dual glucose‑ketone sensing technology that monitors glucose and helps detect rising ketone levels that can lead to a serious health condition known as diabetic ketoacidosis.
Diabetic ketoacidosis is the most common hyperglycemic emergency for people living with diabetes.
According to Abbott, it can develop quickly when the body does not have enough insulin and then starts to break down fat for energy, turning the blood dangerously acidic.
Hospital admissions for diabetic ketoacidosis have increased 55% over the past decade.
